Research overview
What is Pentadeca Arginate (PDA)?
“Pentadeca” refers to fifteen residues, while “arginate” may denote a formulation or counterion in supplier language. Terminology is not standardized enough here to assert that every PDA vial is BPC-157, a particular salt, or a validated new active ingredient. Ask for exact chemical identity and lot-specific documentation in a laboratory context.
What has research examined?
Published BPC-157 experiments include rat models, but they examined named BPC-157 material, not a controlled clinical study of PDA as independently labeled. FDA raises characterization, peptide-impurity, immunogenicity, and insufficient safety-information concerns for proposed compounded BPC-157. These cautions do not prove PDA’s composition or create a shortcut around regulatory requirements.
Do not transfer BPC-157 efficacy claims, safety assertions, or regulatory status to a differently named supplier formulation without direct identity and product-specific evidence. No medical or veterinary use, amount, or preparation is advised.
Research references
- Named BPC-157 material in a rat bowel-adhesion experiment (not PDA evidence)Preclinical BPC-157 context
- FDA safety concerns for proposed compounded BPC-157U.S. Food and Drug Administration
Calculation boundary
The exact sequence, salt/counterion, and mass basis of a product labeled PDA are not established by the name. A mg-to-mL calculation cannot infer constituent potency or identify material.